bluebird bio

BLUE NASDAQ
120.02
+3.03
+2.59%
盘后: 120.02 0 0.00% 17:58 08/16 EDT
开盘
118.09
昨收
116.99
最高
120.34
最低
117.96
成交量
30.46万
成交均量(3M)
55.76万
52周最高
176.55
52周最低
87.49
换手率
0.55%
市值
66.33亿
分时
5日
1月
3月
1年
5年

相关股票

微牛行情栏目提供bluebird bio BLUE股票价格,bluebird bio股票实时行情,公司简介,财报信息,股本结构等,掌握美港股行情走势,开盘价,收盘价,总市值,换手率,市盈率,收益率等数据,及时把握美股港股投资机会。

公司介绍

bluebird bio, Inc. is a clinical-stage biotechnology company. The Company is focused on developing gene therapies for severe diseases and cancer. With its lentiviral-based gene therapy and gene editing capabilities, it has built an integrated product platform with various applications in these areas. The Company's clinical programs in severe genetic diseases include its LentiGlobin product candidate to treat transfusion-dependent b-thalassemia and to treat severe sickle cell disease (SCD) and its Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD). Its programs in oncology focuses on developing T cell-based immunotherapies, including chimeric antigen receptor (CAR) and T cell receptor (TCR) T cell therapies. bb2121, its lead product candidate in oncology, is a CAR T cell product candidate for the treatment of multiple myeloma. It also has discovery research programs utilizing megaTALs/homing endonuclease gene editing technologies for use across its pipeline.
展开 >

最近浏览

名称
价格
涨跌幅